Emerging options in the treatment of bipolar disorders
Abstract
Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include the anticonvulsants, atypical antipsychotics and options such as the omega-3 fatty acids and transcranial magnetic stimulation. Of the anticonvulsants, lamotrigine is currently the agent for which the greatest amount of controlled clinical data is accumulating, particularly in the depressed and rapid cycling phases of the illness. Olanzapine is currently the atypical antipsychotic with the largest body of evidence in mania, although data is emerging on other atypical antipsychotics including risperidone and ziprasidone. Data regarding the atypical agents in other phases of the illness are awaited. The options available for this difficult to treat condition is increasing with the new range of agents.
Read the paper
Related studies
- Promising Sources of Plant-Derived Polyunsaturated Fatty Acids: A Narrative Review
- Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials
- Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials
- The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review
- Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review
- Omega-3 fatty acid nanocarriers: Characterization and potential applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.